









Summary of glycosyltransferases discussed in this review: Catalytic reactions, tumor types reported to date and associated biological consequences




Table 1. Glycosylation alterations in cancer: Causes and consequences for inflammation and metastasis.

Glycosyltransferase	N- or O-glycosylation	Reaction/glycosylation catalyzed	Cancer with reported dysregulation	Biological consequences
Potential causes of glycosylation deregulation in cancer				
B4GALNT2	O – Sd ^a antigen (mainly)	<p style="text-align: center;"><i>Sda antigen</i></p>	Gastric cancer, colorectal cancer	<ul style="list-style-type: none"> In gastrointestinal cancer: Hypermethylation in gastric cancer cells → ↓Sda antigen and ↑SLe antigens → ↑ migration⁴⁹
FUT1	O – H antigen (mainly)	<p style="text-align: center;"><i>H antigen</i></p>	Pancreatic cancer, breast cancer, gastric cancer	<ul style="list-style-type: none"> ↓HIFα (inhibition of hypoxia) → ↑FUT1/FUT2⁴⁰
FUT2	O (mainly)	<p style="text-align: center;"><i>H antigen</i></p>	Pancreatic cancer, colorectal cancer	
FUT3	O – SLe antigens	<p style="text-align: center;"><i>SLeA</i> <i>SLeX</i></p>	Pancreatic cancer, colorectal cancer	<ul style="list-style-type: none"> 5-Aza-dC (methylation inhibitor) → ↑FUT3 → ↑SLe antigens → ↑ metastasis⁴⁸
FUT7	O – CLA/SLe ^x (mainly)	<p style="text-align: center;"><i>SLeX</i></p>	Colorectal cancer	<ul style="list-style-type: none"> Hypoxia → ↑FUT7 → ↑SLe^x⁴³

<p>MGAT4 (GnT-IV)</p>	<p>N</p>	 <p><i>Common pentasaccharide core region</i> → <i>Hybrid or complex N-glycan</i></p>	<p>Pancreatic cancer, leukemia, breast cancer</p>	<ul style="list-style-type: none"> ▪ In pancreatic cancer cells: ↓MGAT4a ↑MGAT4b → 5-Aza-dC (methylation inhibitor) + butyrate → ↑MGAT4a^{47,50}
<p>MGAT5 (GnT-V)</p>	<p>N</p>	 <p><i>Common pentasaccharide core region</i> → <i>Hybrid or complex N-glycan</i></p>	<p>Hepatocellular carcinoma, colorectal cancer</p>	<ul style="list-style-type: none"> ▪ ↓GATA2/GATA3 (HIFα stabilizing transcription factors) → ↓MGAT5⁴² ▪ NM23 (tumor suppressor gene) → ↓MGAT5 → ↓chemotaxis and motility⁴⁶
<p>ST3GAL1</p>	<p>O</p>	 <p><i>T antigen Core 1</i> → <i>Sialyl T antigen</i></p>	<p>Colorectal cancer, breast cancer, ovarian cancer</p>	<ul style="list-style-type: none"> ▪ Hypoxia → ↑ST3Gal1 → ↑SLe^{X43}
<p>ST3GAL4</p>	<p>N (mainly)</p>	 <p><i>Complex N-glycan</i> → <i>Complex N-glycan</i></p>	<p>Colorectal cancer, gastric cancer</p>	<ul style="list-style-type: none"> ▪ ↓GATA2/GATA3 (HIFα stabilizing transcription factors) → ↓ST3Gal4⁴¹

<p>ST3GAL6</p>	<p>N (mainly)</p>	<p style="text-align: center;">N-glycan → ^{α2,3} N-glycan</p>	<p>Colorectal cancer, leukemia</p>	<ul style="list-style-type: none"> 5-Aza-dC (methylation inhibitor) → ↑ST3GAL6 → ↑SLe antigens → ↑ metastasis⁴⁸
<p>Glycosylation deregulation in cancer: Implications for inflammation and metastasis</p>				
<p>B3GNT6 (C3GnT)</p>	<p>O</p>	<p style="text-align: center;">Tn antigen → Core 3</p>	<p>Colorectal cancer, gastric cancer, pancreatic cancer</p>	<ul style="list-style-type: none"> In pancreatic cancer: ↑B3GNT6 → ↑MUC1 glycosylation → ↓α2β1 expression → ↓ tumor growth and metastasis⁹⁶
<p>B4GALNT3</p>	<p>N (mainly)/O</p>	<p style="text-align: center;">Complex N-glycan → Complex N-glycan</p>	<p>Colorectal cancer, neuroblastoma</p>	<ul style="list-style-type: none"> In colon cancer cells: ↑B4GALNT3 → ↑ stemness and invasion via EGFR O-glycosylation⁶⁵
<p>C1GALT1</p>	<p>O</p>	<p style="text-align: center;">Tn antigen → T antigen (Core 1)</p>	<p>Breast cancer, pancreatic cancer, colorectal cancer</p>	<ul style="list-style-type: none"> ↑C1GALT1 → ↑ EGFR O-glycosylation → ↑ tumor progression⁶⁶
<p>FUT3</p>	<p>N/O</p>	<p style="text-align: center;">R-glycan → SLeA / SLeX</p>	<p>Colorectal cancer, gastric cancer</p>	<ul style="list-style-type: none"> ↑ fucosylation of TGF-β receptors by FUT3 → ↑ Smad activation, receptor signaling and metastasis⁶⁸

<p>FUT6</p>	<p>N/O – SLe^x antigen</p>		<p>Head and neck cancer, colorectal cancer, lung cancer</p>	<ul style="list-style-type: none"> ▪ In head and neck cancer: FUT6 regulates proliferation, migration and EMT through EGFR/ERK/STAT signaling⁶⁷ ▪ ↑ fucosylation of TGF-β receptors by FUT6 → ↑ Smad activation, receptor signaling and metastasis⁶⁸
<p>FUT8</p>	<p>N</p>		<p>Breast cancer, hepatocellular carcinoma, lung cancer</p>	<ul style="list-style-type: none"> ▪ In breast cancer cells: ↓FUT8 → ↑E-cadherin function → ↓ migration and invasion⁵⁷ ▪ ↑ fucosylation of TGF-β receptors by FUT8 → ↑ Smad activation, receptor signaling and metastasis^{68,71} ▪ Dysregulation of FUT8 expression → Alteration of the ability of T cells to interaction with regulatory lectins → Modification of activation thresholds, cytokine production and survival¹⁰³
<p>GALNT1</p>	<p>O</p>		<p>Breast cancer, prostate cancer</p>	<ul style="list-style-type: none"> ▪ ↑GALNT1 → ↑ O-glycosylation of CD44 → Activation of Wnt/β-catenin signaling → ↑ proliferation, migration and invasion⁶⁴
<p>MGAT3 (GnT-III)</p>	<p>N</p>		<p>Melanoma, breast cancer, hepatocellular carcinoma</p>	<ul style="list-style-type: none"> ▪ ↑MGAT3 → ↓ TGF-β-driven cell motility and EMT⁷⁴ ▪ In melanoma: ↑MGAT3 → ↓ cell adhesion, invasiveness and motility⁹²

<p>MGAT5 (GnT-V)</p>	<p>N</p>	 <p style="text-align: center;"> <i>Common pentasaccharide core region</i> → <i>Hybrid or complex N-glycan</i> </p>	<p>Fibrosarcoma, gastric cancer, melanoma, breast cancer, colorectal cancer, ...</p>	<ul style="list-style-type: none"> ▪ In fibrosarcoma: ↑MGAT5 → ↓ function of N-cadherin/E-cadherin → ↓ homotypic adhesion of cancer cells to neighboring cells⁵⁵ ▪ In gastric cancer cells: ↑ glycosylation by MGAT5 of E-cadherin → Disruption of its cellular localization, cis-dimer formation, molecular assembly, adhesion junction stability and cell-cell aggregation⁵⁶ ▪ ↓MGAT5 → ↓ TGF-β-induced EMT⁷³ ▪ In melanoma: ↑MGAT5 → ↑ β1-6-branched structures on N-glycans → ↑ metastasis⁹² ▪ Dysregulation of MGAT5 expression → Alteration of the ability of T cells to interaction with regulatory lectins → Modification of activation thresholds, cytokine production and survival¹⁰³
<p>POFUT1</p>	<p>O – EGF repeats</p>		<p>Colorectal cancer, leukemia</p>	<ul style="list-style-type: none"> ▪ ↑POFUT1 and POGLUT1 → ↑ NOTCH surface expression, activation and transcription of target genes⁷⁷
<p>POGLUT1</p>	<p>O – EGF repeats</p>		<p>Colorectal cancer, leukemia</p>	















<p>ST3GAL4</p>	<p>N (mainly)</p>	 <p>Complex N-glycan</p> <p>Complex N-glycan</p>	<p>Colorectal cancer, gastric cancer</p>	<ul style="list-style-type: none"> ▪ \downarrowST3GAL4 \rightarrow \uparrow transition toward an inflammatory dendritic cell phenotype¹⁰²
<p>ST6GAL1</p>	<p>N</p>	 <p>Complex N-glycan</p> <p>Complex N-glycan</p>	<p>Non-small cell lung cancer, colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer</p>	<ul style="list-style-type: none"> ▪ \downarrowST6Gal1 \rightarrow \downarrow Mesenchymal phenotype⁷² ▪ In non-small cell lung cancer cells: \downarrowST6Gal1 \rightarrow \downarrow NOTCH1 expression \rightarrow \downarrow proliferation, invasion and metastasis⁷⁸ ▪ In colon cancer cells: \uparrowST6Gal1 \rightarrow \uparrow β1 integrin and talin sialylation \rightarrow \uparrow collagen IV expression \rightarrow \uparrow invasion and motility⁹⁵ ▪ \downarrowST6Gal1 \rightarrow \uparrow transition toward an inflammatory dendritic cell phenotype^{101,102} ▪ Dysregulation of ST6Gal1 expression \rightarrow Alteration of the ability of T cells to interaction with regulatory lectins \rightarrow Modification of activation thresholds, cytokine production and survival¹⁰³

Table 2. Platelet-mediated glycoprotein remodeling in cancer cells as a driver of inflammation and metastasis.

Glycosyltransferase	N- or O-glycosylation	Catalyzed reaction	Type(s) of cancer	Biological consequences
Extracellular glycosylation				
B3GNT3	O (mainly)	 <p style="text-align: center;">B3GNT + B4GalT</p> <p style="text-align: center;">Complex N-glycan → Complex N-glycan</p> <p style="text-align: center;">Poly-N-acetyllactosamine (Galβ1-4GlcNAc)_n</p>	Colorectal cancer, gastric cancer, lung adenocarcinoma, cervical cancer	<ul style="list-style-type: none"> ▪ In lung adenocarcinoma: ↑B3GNT3 → ↑ immune cell infiltration¹⁴⁰ ▪ In cervical cancer: ↑B3GNT3 → ↑ pelvic lymph node metastasis¹⁴¹
B4GALT	N/O	 <p style="text-align: center;">B3GNT + B4GalT</p> <p style="text-align: center;">Complex N-glycan → Complex N-glycan</p>	Breast cancer, colorectal cancer, hepatocellular carcinoma	_122
MGAT2 (GnT-II)	N	 <p style="text-align: center;">MGAT2</p> <p style="text-align: center;">Common pentasaccharide core region → Hybrid or complex N-glycan</p>	Hepatocellular carcinoma, colorectal cancer, neuroblastoma	<ul style="list-style-type: none"> ▪ In neuroblastoma: ↑MGAT2 → ↑ complex N-glycan branching → ↑ proliferation and invasion¹³⁸
MGAT3 (GnT-III)	N	 <p style="text-align: center;">MGAT3</p> <p style="text-align: center;">Common pentasaccharide core region → Bisecting N-glycan</p>	Breast cancer, hepatocellular carcinoma, melanoma	<ul style="list-style-type: none"> ▪ In breast cancer and melanoma: ↑MGAT3 → ↓EMT → ↓ metastasis and dissemination^{92,139}

<p>ST3GAL1</p>	<p>O</p>	 <p>Ser/Thr — [GalNAc] — [Gal] $\xrightarrow{\text{ST3Gal1}}$ R — [GlcNAc] — [Gal] — NeuAc_{α2,3}</p> <p><i>T antigen Core 1</i> <i>Sialyl T antigen</i></p>	<p>Breast cancer, ovarian cancer</p>	<p>_122</p>
-----------------------	----------	--	--	-------------

Legend:

-  N-acetylglucosamine (GlcNAc)
-  Mannose (Man)
-  Glucose (Glc)
-  Galactose (Gal)
-  N-acetylneuraminic acid (NeuAc)
-  Fucose (Fuc)
-  N-acetylgalactosamine (GalNAc)